NASDAQ · LLY
Healthcare · Drug Manufacturers - General
$1,166.51
Up+$48.20 (+4.13%)
Updated Oct 14, 2026, 4:11 PM
SID Score
6.4/10
Composite research score
Smart Money
44/100
Neutral
Price performance · LLY
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 13, 2026
LLY closed at $1,166.51 after 21 trading sessions, up 2.68% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 13, 2026 | $1,190.70 | $1,193.30 | $1,158.405 | $1,166.51 | 1.84M |
| Oct 12, 2026 | $1,181.24 | $1,188.70 | $1,172.805 | $1,182.62 | 1.25M |
| Oct 9, 2026 | $1,153.56 | $1,179.82 | $1,151.67 | $1,179.27 | 1.39M |
| Oct 8, 2026 | $1,183.50 | $1,186.0903 | $1,131.21 | $1,169.60 | 3.09M |
| Oct 7, 2026 | $1,173.62 | $1,206.63 | $1,166.00 | $1,188.72 | 2.31M |
| Oct 6, 2026 | $1,147.15 | $1,177.065 | $1,139.98 | $1,157.49 | 2.13M |
| Oct 5, 2026 | $1,150.76 | $1,165.73 | $1,139.495 | $1,143.12 | 1.98M |
| Oct 2, 2026 | $1,153.82 | $1,164.9155 | $1,136.66 | $1,142.85 | 2.05M |
| Oct 1, 2026 | $1,155.00 | $1,158.72 | $1,139.85 | $1,149.85 | 2.17M |
| Sep 30, 2026 | $1,186.49 | $1,215.00 | $1,155.27 | $1,157.08 | 3.41M |
| Sep 29, 2026 | $1,186.05 | $1,192.94 | $1,168.471 | $1,184.63 | 1.66M |
| Sep 28, 2026 | $1,180.30 | $1,194.09 | $1,172.56 | $1,184.78 | 1.97M |
| Sep 25, 2026 | $1,185.32 | $1,190.00 | $1,160.84 | $1,183.46 | 1.92M |
| Sep 24, 2026 | $1,156.67 | $1,197.79 | $1,151.00 | $1,181.89 | 2.42M |
| Sep 23, 2026 | $1,174.71 | $1,188.88 | $1,145.98 | $1,150.99 | 2.16M |
| Sep 22, 2026 | $1,146.15 | $1,180.53 | $1,139.26 | $1,170.14 | 2.45M |
| Sep 21, 2026 | $1,144.495 | $1,170.8999 | $1,134.41 | $1,164.89 | 2.48M |
| Sep 18, 2026 | $1,150.00 | $1,157.60 | $1,140.27 | $1,152.93 | 4.55M |
| Sep 17, 2026 | $1,150.27 | $1,159.75 | $1,138.26 | $1,152.44 | 1.9M |
| Sep 16, 2026 | $1,137.31 | $1,151.23 | $1,132.63 | $1,137.82 | 1.48M |
| Sep 15, 2026 | $1,156.63 | $1,161.00 | $1,131.59 | $1,136.11 | 1.89M |
The latest Smart Investors Daily articles mentioning LLY.
Company
Market Activity
Research & News
LLY research
Company profile and research snapshot.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 12, 2026 | RBC Capital | Outperform | — |
| Oct 8, 2026 | Cantor Fitzgerald | Overweight | — |
| Oct 7, 2026 | Morgan Stanley | Overweight | — |
| Sep 28, 2026 | JP Morgan | Overweight | — |
| Sep 22, 2026 | TD Cowen | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 14, 2026
Viking is set to begin two simultaneous studies of VK2735 in a Phase 3 trial after Phase 2 showed weight reductions of up to 12.2% after 13 weeks.
Yahoo · Oct 14, 2026
Johnson & Johnson (JNJ) has introduced several new drugs recently, and current buyers of its stock may be betting on their commercial success. The lineup includes ICOTYDE, an oral treatment for plaque psoriasis. The company has yet to disclose sales figures for the medication. How much the drug can ultimately add to J&J remains an open question. Anyone purchasing shares today takes on that unknown before the answer is in.
Yahoo · Oct 14, 2026
With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-related conditions.
Yahoo · Oct 14, 2026
Johnson and Johnson crushed earnings, raised guidance, and still watched its stock crater nearly 6% in a single session. Understanding what spooked investors reveals whether Tuesday's selloff is a trap or a warning.
Interpretive context generated from the platform’s current data sources.
Eli Lilly and Company shares closed at $1,166.51, reflecting a daily decline of 1.66% per SID market data. Despite the near-term pullback, the stock has demonstrated resilience across longer timeframes, posting gains of 2.48% over the past month, 0.85% over three months, and 8.24% over the trailing twelve months. LLY currently trades below its 50-day moving average of $1,175.55 but remains well above its 200-day moving average of $1,072.24, suggesting the intermediate-term uptrend remains intact. The 14-day relative strength index stands at 54.6, indicating neutral momentum with no overbought or oversold conditions, according to SID market data. Average daily trading volume registers at approximately 3.8 million shares. The stock carries a beta of 0.369, reflecting significantly lower volatility than the broader market. Eli Lilly's market capitalization stands at approximately $906.5 billion, positioning it among the largest healthcare companies globally.
Eli Lilly trades at a price-to-earnings ratio of 49.16, a substantial premium relative to the broader healthcare sector, according to SID market data. The company's PEG ratio of 1.47 contextualizes this elevated multiple against its projected earnings growth, suggesting the market is pricing in continued expansion from key therapeutic franchises. The price-to-book ratio stands at 38.04, reflecting significant intangible asset value embedded in the company's pharmaceutical pipeline and brand portfolio, per SEC filings. Eli Lilly offers a modest dividend yield of 0.59%, consistent with its capital allocation strategy that prioritizes reinvestment in research and development. These valuation metrics collectively indicate that investors are assigning a growth premium to the company, largely driven by its GLP-1 receptor agonist portfolio. The healthcare sector classification provides some defensive characteristics, though the premium valuation introduces sensitivity to any deceleration in revenue or pipeline progress.
Eli Lilly's composite smart money score registers at 44 out of 100 with a neutral signal, per SID market data. The institutional component scores a perfect 25 out of 25, indicating maximum institutional conviction and sustained accumulation by large asset managers. In contrast, the insider sentiment score sits at 7.2 out of 25, reflecting more tempered confidence from company executives. According to SEC Form 4 filings, there have been 16 insider transactions over the past 90 days, comprising 9 purchases and 7 sales. This relatively balanced insider activity suggests no decisive directional bias from management. The dark pool activity score stands at 9.1 out of 25, indicating moderate levels of off-exchange institutional trading. Congressional trading activity scores just 3.2 out of 25, showing minimal reported legislative interest in the stock. The divergence between strong institutional ownership signals and subdued insider and congressional scores creates a mixed overall smart money profile for Eli Lilly, warranting continued monitoring of Form 4 filings for directional shifts.
Eli Lilly has delivered consecutive earnings beats in its two most recent reported quarters, according to company earnings reports. In the quarter ending August 2026, the company reported earnings per share of $8.38 against an analyst consensus estimate of $6.01, representing a positive surprise of $2.37, or approximately 39.4%. The prior quarter saw EPS of $8.55 versus estimates of $6.85, yielding a $1.70 upside surprise of roughly 24.8%. These substantial beats underscore the company's capacity to outperform Wall Street expectations, driven by accelerating revenue from key growth products. Looking ahead, analyst estimates project EPS of $8.84 for the quarter reporting in August 2026 and $7.89 for the October 2026 quarter, per consensus data. The forward estimates imply continued robust profitability. The pattern of significant earnings outperformance supports the growth narrative embedded in the stock's premium valuation multiples.
Wall Street consensus on Eli Lilly remains uniformly bullish, with all five most recent analyst actions reiterating positive ratings, per SID consensus data. On October 12, 2026, RBC Capital maintained its Outperform rating, while Cantor Fitzgerald reiterated an Overweight stance on October 8. Morgan Stanley followed on October 7 with a maintained Overweight rating, and JP Morgan reaffirmed its Overweight designation on September 28, according to Wall Street analyst reports. TD Cowen also sustained its Buy rating on September 22. Notably, none of these actions represented upgrades or downgrades, indicating stable conviction among major sell-side firms. The absence of any bearish revisions across these five prominent institutions reflects broad confidence in Eli Lilly's commercial trajectory and pipeline catalysts. The consistency of maintained ratings rather than fresh upgrades suggests analysts view the current valuation as already reflecting strong fundamentals while still warranting a positive outlook for additional upside potential.
The latest Smart Investors Daily articles mentioning LLY.
